ID   IBP3_HUMAN              Reviewed;         291 AA.
AC   P17936; A4D2F5; D3DVM0; Q2V509; Q6P1M6; Q9UCL4;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2007, sequence version 2.
DT   18-JUN-2025, entry version 246.
DE   RecName: Full=Insulin-like growth factor-binding protein 3;
DE            Short=IBP-3;
DE            Short=IGF-binding protein 3;
DE            Short=IGFBP-3;
DE   Flags: Precursor;
GN   Name=IGFBP3; Synonyms=IBP3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLY-32.
RX   PubMed=2464130; DOI=10.1210/mend-2-12-1176;
RA   Wood W.I., Cachianes G., Henzel W.J., Winslow G.A., Spencer S.A.,
RA   Hellmiss R., Martin J.L., Baxter R.C.;
RT   "Cloning and expression of the growth hormone-dependent insulin-like growth
RT   factor-binding protein.";
RL   Mol. Endocrinol. 2:1176-1185(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT GLY-32.
RX   PubMed=1695633; DOI=10.1016/s0021-9258(19)38392-9;
RA   Cubbage M.L., Suwanichkul A., Powell D.R.;
RT   "Insulin-like growth factor binding protein-3. Organization of the human
RT   chromosomal gene and demonstration of promoter activity.";
RL   J. Biol. Chem. 265:12642-12649(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLY-32.
RC   TISSUE=Skin;
RX   PubMed=7508771; DOI=10.3109/10425179309015621;
RA   Thweatt R., Fleischmann R., Goldstein S.;
RT   "Analysis of the primary structure of insulin-like growth factor binding
RT   protein-3 cDNA from Werner syndrome fibroblasts.";
RL   DNA Seq. 4:43-46(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANTS THR-56 AND
RP   SER-234.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney, and Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 28-65.
RX   PubMed=1697583; DOI=10.1016/s0021-9258(18)77200-1;
RA   Zapf J., Kiefer M., Merryweather J., Musiarz F., Bauer D., Born W.,
RA   Fischer J.A., Froesch E.R.;
RT   "Isolation from adult human serum of four insulin-like growth factor (IGF)
RT   binding proteins and molecular cloning of one of them that is increased by
RT   IGF I administration and in extrapancreatic tumor hypoglycemia.";
RL   J. Biol. Chem. 265:14892-14898(1990).
RN   [10]
RP   PROTEIN SEQUENCE OF 28-45, INTERACTION WITH IGF2, AND VARIANT GLY-32.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=1726837;
RA   Roghani M., Segovia B., Whitechurch O., Binoux M.;
RT   "Purification from human cerebrospinal fluid of insulin-like growth factor
RT   binding proteins (IGFBPs). Isolation of IGFBP-2, an altered form of IGFBP-3
RT   and a new IGFBP species.";
RL   Growth Regul. 1:125-130(1991).
RN   [11]
RP   PROTEIN SEQUENCE OF 28-42.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH LRP1.
RX   PubMed=9252371; DOI=10.1074/jbc.272.33.20572;
RA   Leal S.M., Liu Q., Huang S.S., Huang J.S.;
RT   "The type V transforming growth factor beta receptor is the putative
RT   insulin-like growth factor-binding protein 3 receptor.";
RL   J. Biol. Chem. 272:20572-20576(1997).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RXRA.
RX   PubMed=10874028; DOI=10.1074/jbc.m002547200;
RA   Liu B., Lee H.Y., Weinzimer S.A., Powell D.R., Clifford J.L., Kurie J.M.,
RA   Cohen P.;
RT   "Direct functional interactions between insulin-like growth factor-binding
RT   protein-3 and retinoid X receptor-alpha regulate transcriptional signaling
RT   and apoptosis.";
RL   J. Biol. Chem. 275:33607-33613(2000).
RN   [14]
RP   INTERACTION WITH HUMANIN.
RX   PubMed=14561895; DOI=10.1073/pnas.2135111100;
RA   Ikonen M., Liu B., Hashimoto Y., Ma L., Lee K.W., Niikura T., Nishimoto I.,
RA   Cohen P.;
RT   "Interaction between the Alzheimer's survival peptide humanin and insulin-
RT   like growth factor-binding protein 3 regulates cell survival and
RT   apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:13042-13047(2003).
RN   [15]
RP   FUNCTION.
RX   PubMed=15371331; DOI=10.1096/fj.04-1872fje;
RA   Huang S.S., Leal S.M., Chen C.L., Liu I.H., Huang J.S.;
RT   "Identification of insulin receptor substrate proteins as key molecules for
RT   the TbetaR-V/LRP-1-mediated growth inhibitory signaling cascade in
RT   epithelial and myeloid cells.";
RL   FASEB J. 18:1719-1721(2004).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-136.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-136 AND ASN-199.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-136.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   GLYCOSYLATION AT ASN-116; ASN-136 AND ASN-199.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [20]
RP   FUNCTION, PHOSPHORYLATION AT SER-194 AND SER-202, MUTAGENESIS OF SER-194
RP   AND SER-202, AND SUBCELLULAR LOCATION.
RX   PubMed=19556345; DOI=10.1210/me.2008-0365;
RA   Cobb L.J., Mehta H., Cohen P.;
RT   "Enhancing the apoptotic potential of insulin-like growth factor-binding
RT   protein-3 in prostate cancer by modulation of CK2 phosphorylation.";
RL   Mol. Endocrinol. 23:1624-1633(2009).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TMEM219.
RX   PubMed=20353938; DOI=10.1074/jbc.m110.122226;
RA   Ingermann A.R., Yang Y.F., Han J., Mikami A., Garza A.E., Mohanraj L.,
RA   Fan L., Idowu M., Ware J.L., Kim H.S., Lee D.Y., Oh Y.;
RT   "Identification of a novel cell death receptor mediating IGFBP-3-induced
RT   anti-tumor effects in breast and prostate cancer.";
RL   J. Biol. Chem. 285:30233-30246(2010).
RN   [22]
RP   PHOSPHORYLATION AT SER-148 AND SER-201.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-7 AND CYS-252.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH HUMANIN.
RX   PubMed=19623253; DOI=10.1371/journal.pone.0006334;
RA   Muzumdar R.H., Huffman D.M., Atzmon G., Buettner C., Cobb L.J., Fishman S.,
RA   Budagov T., Cui L., Einstein F.H., Poduval A., Hwang D., Barzilai N.,
RA   Cohen P.;
RT   "Humanin: a novel central regulator of peripheral insulin action.";
RL   PLoS ONE 4:e6334-e6334(2009).
RN   [25]
RP   FUNCTION.
RX   PubMed=19952275; DOI=10.1210/en.2009-0577;
RA   Lue Y., Swerdloff R., Liu Q., Mehta H., Hikim A.S., Lee K.W., Jia Y.,
RA   Hwang D., Cobb L.J., Cohen P., Wang C.;
RT   "Opposing roles of insulin-like growth factor binding protein 3 and humanin
RT   in the regulation of testicular germ cell apoptosis.";
RL   Endocrinology 151:350-357(2010).
RN   [26]
RP   INTERACTION WITH HUMANIN.
RX   PubMed=26216267; DOI=10.2174/0929866522666150728114955;
RA   Njomen E., Evans H.G., Gedara S.H., Heyl D.L.;
RT   "Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3
RT   (IGFBP3) and Regulates Its Interaction with Importin-beta.";
RL   Protein Pept. Lett. 22:869-876(2015).
RN   [27] {ECO:0007744|PDB:7WRQ}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.60 ANGSTROMS) OF 28-291, INTERACTION
RP   WITH IGF1 AND ALS, DISULFIDE BOND, AND MUTAGENESIS OF ARG-215.
RX   PubMed=35907924; DOI=10.1038/s41467-022-32214-2;
RA   Kim H., Fu Y., Hong H.J., Lee S.G., Lee D.S., Kim H.M.;
RT   "Structural basis for assembly and disassembly of the IGF/IGFBP/ALS ternary
RT   complex.";
RL   Nat. Commun. 13:4434-4434(2022).
CC   -!- FUNCTION: Multifunctional protein that plays a critical role in
CC       regulating the availability of IGFs such as IGF1 and IGF2 to their
CC       receptors and thereby regulates IGF-mediated cellular processes
CC       including proliferation, differentiation, and apoptosis in a cell-type
CC       specific manner (PubMed:10874028, PubMed:19556345). Also exhibits IGF-
CC       independent antiproliferative and apoptotic effects mediated by its
CC       receptor TMEM219/IGFBP-3R (PubMed:20353938). Inhibits the positive
CC       effect of humanin on insulin sensitivity (PubMed:19623253). Promotes
CC       testicular germ cell apoptosis (PubMed:19952275). Acts via LRP-
CC       1/alpha2M receptor, also known as TGF-beta type V receptor, to mediate
CC       cell growth inhibition independent of IGF1 (PubMed:9252371).
CC       Mechanistically, induces serine-specific dephosphorylation of IRS1 or
CC       IRS2 upon ligation to its receptor, leading to the inhibitory cascade
CC       (PubMed:15371331). In the nucleus, interacts with transcription factors
CC       such as retinoid X receptor-alpha/RXRA to regulate transcriptional
CC       signaling and apoptosis (PubMed:10874028).
CC       {ECO:0000269|PubMed:10874028, ECO:0000269|PubMed:15371331,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19556345,
CC       ECO:0000269|PubMed:19623253, ECO:0000269|PubMed:19952275,
CC       ECO:0000269|PubMed:20353938}.
CC   -!- SUBUNIT: Interacts with XLKD1 (By similarity). Binds IGF2 more than
CC       IGF1. Forms a ternary complex of about 140 to 150 kDa with IGF1 or IGF2
CC       and a 85 kDa glycoprotein (ALS) (PubMed:35907924). Interacts with
CC       humanin; humanin competes with importin KPNB1 for binding to IGFBP3,
CC       blocking IGFBP3 nuclear import and IGFBP3-mediated apoptosis
CC       (PubMed:14561895, PubMed:19623253, PubMed:26216267). Interacts with
CC       TMEM219. Interacts with RXRA; this interaction modulates the
CC       transcriptional activity of RXRA (PubMed:10874028). Interacts with
CC       LRP1; this interaction mediates cell growth inhibition independent of
CC       IGF1 (PubMed:9252371). {ECO:0000250, ECO:0000269|PubMed:10874028,
CC       ECO:0000269|PubMed:14561895, ECO:0000269|PubMed:1726837,
CC       ECO:0000269|PubMed:19623253, ECO:0000269|PubMed:20353938,
CC       ECO:0000269|PubMed:26216267, ECO:0000269|PubMed:35907924}.
CC   -!- INTERACTION:
CC       P17936; P00533: EGFR; NbExp=3; IntAct=EBI-715709, EBI-297353;
CC       P17936; Q92993: KAT5; NbExp=3; IntAct=EBI-715709, EBI-399080;
CC       P17936; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-715709, EBI-11742507;
CC       P17936; Q8IVG9: MT-RNR2; NbExp=7; IntAct=EBI-715709, EBI-8643752;
CC       P17936; P17252: PRKCA; NbExp=3; IntAct=EBI-715709, EBI-1383528;
CC       P17936; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-715709, EBI-9090795;
CC       P17936; Q86XT9: TMEM219; NbExp=8; IntAct=EBI-715709, EBI-20264080;
CC       P17936; P61981: YWHAG; NbExp=3; IntAct=EBI-715709, EBI-359832;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:20353938}. Nucleus
CC       {ECO:0000269|PubMed:10874028, ECO:0000269|PubMed:19556345}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P17936-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P17936-2; Sequence=VSP_047293;
CC   -!- TISSUE SPECIFICITY: Expressed by most tissues. Present in plasma.
CC   -!- DEVELOPMENTAL STAGE: IGFBP3 levels are higher during extrauterine life
CC       and peak during puberty.
CC   -!- INDUCTION: Up-regulated in the presence of IGF1, insulin and other
CC       growth-stimulating factors such as growth hormone, EGF and phorbol
CC       esters.
CC   -!- DOMAIN: The thyroglobulin type-1 domain mediates interaction with HN.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       Phosphorylated by CK2; resulting in decreased nuclear localization
CC       (PubMed:19556345). {ECO:0000269|PubMed:19556345,
CC       ECO:0000269|PubMed:26091039}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M31159; AAA52541.1; -; mRNA.
DR   EMBL; M35878; AAA52706.1; -; Genomic_DNA.
DR   EMBL; X64875; CAA46087.1; -; mRNA.
DR   EMBL; DQ301819; ABB96247.1; -; Genomic_DNA.
DR   EMBL; AC091524; AAS07554.1; -; Genomic_DNA.
DR   EMBL; CH236958; EAL23801.1; -; Genomic_DNA.
DR   EMBL; CH471128; EAW61028.1; -; Genomic_DNA.
DR   EMBL; CH471128; EAW61029.1; -; Genomic_DNA.
DR   EMBL; BC000013; AAH00013.1; -; mRNA.
DR   EMBL; BC018962; AAH18962.1; -; mRNA.
DR   EMBL; BC064987; AAH64987.1; -; mRNA.
DR   CCDS; CCDS34632.1; -. [P17936-2]
DR   CCDS; CCDS5505.1; -. [P17936-1]
DR   PIR; A36578; IOHU3.
DR   RefSeq; NP_000589.2; NM_000598.5. [P17936-1]
DR   RefSeq; NP_001013416.1; NM_001013398.2. [P17936-2]
DR   RefSeq; XP_016867641.1; XM_017012152.1.
DR   RefSeq; XP_047276281.1; XM_047420325.1. [P17936-1]
DR   PDB; 7WRQ; EM; 3.60 A; B=28-291.
DR   PDBsum; 7WRQ; -.
DR   AlphaFoldDB; P17936; -.
DR   EMDB; EMD-32735; -.
DR   SMR; P17936; -.
DR   BioGRID; 109707; 58.
DR   CORUM; P17936; -.
DR   DIP; DIP-40786N; -.
DR   FunCoup; P17936; 279.
DR   IntAct; P17936; 38.
DR   MINT; P17936; -.
DR   STRING; 9606.ENSP00000370473; -.
DR   BindingDB; P17936; -.
DR   ChEMBL; CHEMBL3997; -.
DR   DrugBank; DB00523; Alitretinoin.
DR   DrugBank; DB01277; Mecasermin.
DR   MEROPS; I31.952; -.
DR   GlyConnect; 1945; 6 N-Linked glycans (3 sites).
DR   GlyCosmos; P17936; 5 sites, 10 glycans.
DR   GlyGen; P17936; 14 sites, 24 N-linked glycans (3 sites), 4 O-linked glycans (11 sites).
DR   iPTMnet; P17936; -.
DR   PhosphoSitePlus; P17936; -.
DR   BioMuta; IGFBP3; -.
DR   DMDM; 146327827; -.
DR   jPOST; P17936; -.
DR   MassIVE; P17936; -.
DR   PaxDb; 9606-ENSP00000370473; -.
DR   PeptideAtlas; P17936; -.
DR   ProteomicsDB; 53527; -. [P17936-1]
DR   Antibodypedia; 872; 754 antibodies from 44 providers.
DR   DNASU; 3486; -.
DR   Ensembl; ENST00000381083.9; ENSP00000370473.4; ENSG00000146674.16. [P17936-2]
DR   Ensembl; ENST00000613132.5; ENSP00000477772.2; ENSG00000146674.16. [P17936-1]
DR   GeneID; 3486; -.
DR   KEGG; hsa:3486; -.
DR   MANE-Select; ENST00000613132.5; ENSP00000477772.2; NM_000598.5; NP_000589.2.
DR   UCSC; uc003tnr.4; human. [P17936-1]
DR   AGR; HGNC:5472; -.
DR   CTD; 3486; -.
DR   DisGeNET; 3486; -.
DR   GeneCards; IGFBP3; -.
DR   HGNC; HGNC:5472; IGFBP3.
DR   HPA; ENSG00000146674; Tissue enhanced (liver, placenta).
DR   MIM; 146732; gene.
DR   OpenTargets; ENSG00000146674; -.
DR   VEuPathDB; HostDB:ENSG00000146674; -.
DR   eggNOG; ENOG502QWC0; Eukaryota.
DR   GeneTree; ENSGT00940000158092; -.
DR   InParanoid; P17936; -.
DR   OMA; CKPLVPD; -.
DR   OrthoDB; 6068400at2759; -.
DR   PAN-GO; P17936; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; P17936; -.
DR   PathwayCommons; P17936; -.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   SignaLink; P17936; -.
DR   SIGNOR; P17936; -.
DR   BioGRID-ORCS; 3486; 13 hits in 1154 CRISPR screens.
DR   ChiTaRS; IGFBP3; human.
DR   GeneWiki; IGFBP3; -.
DR   GenomeRNAi; 3486; -.
DR   Pharos; P17936; Tchem.
DR   PRO; PR:P17936; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P17936; protein.
DR   Bgee; ENSG00000146674; Expressed in decidua and 200 other cell types or tissues.
DR   ExpressionAtlas; P17936; baseline and differential.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0016942; C:insulin-like growth factor binding protein complex; IC:BHF-UCL.
DR   GO; GO:0042567; C:insulin-like growth factor ternary complex; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0001968; F:fibronectin binding; IBA:GO_Central.
DR   GO; GO:0005520; F:insulin-like growth factor binding; NAS:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL.
DR   GO; GO:0031995; F:insulin-like growth factor II binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; NAS:UniProtKB.
DR   GO; GO:0008160; F:protein tyrosine phosphatase activator activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0000165; P:MAPK cascade; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IGI:MGI.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:0009968; P:negative regulation of signal transduction; NAS:UniProtKB.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IDA:BHF-UCL.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0001558; P:regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0043567; P:regulation of insulin-like growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0044342; P:type B pancreatic cell proliferation; IEA:Ensembl.
DR   CDD; cd00191; TY; 1.
DR   FunFam; 4.10.40.20:FF:000001; Insulin-like growth factor binding protein 5; 1.
DR   FunFam; 4.10.800.10:FF:000005; Putative insulin-like growth factor-binding protein 5; 1.
DR   Gene3D; 4.10.40.20; -; 1.
DR   Gene3D; 4.10.800.10; Thyroglobulin type-1; 1.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR012211; IGFBP-3.
DR   InterPro; IPR000867; IGFBP-like.
DR   InterPro; IPR022321; IGFBP_1-6_chordata.
DR   InterPro; IPR017891; Insulin_GF-bd_Cys-rich_CS.
DR   InterPro; IPR000716; Thyroglobulin_1.
DR   InterPro; IPR036857; Thyroglobulin_1_sf.
DR   PANTHER; PTHR11551; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN; 1.
DR   PANTHER; PTHR11551:SF3; INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 3; 1.
DR   Pfam; PF00219; IGFBP; 1.
DR   Pfam; PF00086; Thyroglobulin_1; 1.
DR   PRINTS; PR01976; IGFBPFAMILY.
DR   PRINTS; PR01979; IGFBPFAMILY3.
DR   SMART; SM00121; IB; 1.
DR   SMART; SM00211; TY; 1.
DR   SUPFAM; SSF57184; Growth factor receptor domain; 1.
DR   SUPFAM; SSF57610; Thyroglobulin type-1 domain; 1.
DR   PROSITE; PS00222; IGFBP_N_1; 1.
DR   PROSITE; PS51323; IGFBP_N_2; 1.
DR   PROSITE; PS00484; THYROGLOBULIN_1_1; 1.
DR   PROSITE; PS51162; THYROGLOBULIN_1_2; 1.
DR   neXtProt; NX_P17936; -.
DR   PharmGKB; PA29705; -.
DR   TreeFam; TF331211; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Growth factor binding; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome; Secreted;
KW   Signal.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000269|PubMed:15340161,
FT                   ECO:0000269|PubMed:1697583, ECO:0000269|PubMed:1726837"
FT   CHAIN           28..291
FT                   /note="Insulin-like growth factor-binding protein 3"
FT                   /id="PRO_0000014378"
FT   DOMAIN          36..117
FT                   /note="IGFBP N-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00653"
FT   DOMAIN          210..285
FT                   /note="Thyroglobulin type-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00500"
FT   REGION          28..134
FT                   /note="IGF-binding"
FT                   /evidence="ECO:0000255"
FT   REGION          130..162
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          189..211
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        146..156
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        191..202
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         148
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   MOD_RES         194
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:19556345"
FT   MOD_RES         201
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   MOD_RES         202
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:19556345"
FT   CARBOHYD        116
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19139490"
FT   CARBOHYD        136
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14760718,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        199
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19139490"
FT   DISULFID        40..67
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   DISULFID        43..69
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   DISULFID        51..70
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   DISULFID        58..73
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   DISULFID        81..94
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   DISULFID        88..114
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   DISULFID        213..240
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   DISULFID        251..262
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   DISULFID        264..285
FT                   /evidence="ECO:0000269|PubMed:35907924,
FT                   ECO:0007744|PDB:7WRQ"
FT   VAR_SEQ         135
FT                   /note="G -> GEPPAPG (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047293"
FT   VARIANT         7
FT                   /note="T -> M (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs754430221)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036279"
FT   VARIANT         32
FT                   /note="A -> G (in dbSNP:rs2854746)"
FT                   /evidence="ECO:0000269|PubMed:1695633,
FT                   ECO:0000269|PubMed:1726837, ECO:0000269|PubMed:2464130,
FT                   ECO:0000269|PubMed:7508771"
FT                   /id="VAR_025262"
FT   VARIANT         56
FT                   /note="A -> T (in dbSNP:rs34257987)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_025263"
FT   VARIANT         158
FT                   /note="H -> P (in dbSNP:rs9282734)"
FT                   /id="VAR_021974"
FT   VARIANT         234
FT                   /note="G -> S (in dbSNP:rs35712717)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_025264"
FT   VARIANT         252
FT                   /note="R -> C (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs538312081)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036280"
FT   MUTAGEN         194
FT                   /note="S->A: Strongly enhanced apoptotic potential."
FT                   /evidence="ECO:0000269|PubMed:19556345"
FT   MUTAGEN         202
FT                   /note="S->A: No change in apoptotic potential."
FT                   /evidence="ECO:0000269|PubMed:19556345"
FT   MUTAGEN         215
FT                   /note="R->E: Completely abolished ALS binding."
FT                   /evidence="ECO:0000269|PubMed:35907924"
SQ   SEQUENCE   291 AA;  31674 MW;  A9682065AB266586 CRC64;
     MQRARPTLWA AALTLLVLLR GPPVARAGAS SAGLGPVVRC EPCDARALAQ CAPPPAVCAE
     LVREPGCGCC LTCALSEGQP CGIYTERCGS GLRCQPSPDE ARPLQALLDG RGLCVNASAV
     SRLRAYLLPA PPAPGNASES EEDRSAGSVE SPSVSSTHRV SDPKFHPLHS KIIIIKKGHA
     KDSQRYKVDY ESQSTDTQNF SSESKRETEY GPCRREMEDT LNHLKFLNVL SPRGVHIPNC
     DKKGFYKKKQ CRPSKGRKRG FCWCVDKYGQ PLPGYTTKGK EDVHCYSMQS K
//
